After nine years of refinement at Fred Hutchinson Cancer Center in Seattle, a different kind of HIV vaccine candidate is nearing its first testing in human volunteers.
This innovative HIV vaccine is intended to train a person’s immune system to mount a robust antibody response against the virus that causes AIDS.
The HVTN 301 phase 1 clinical trial is among the first studies to try out this next-generation vaccine concept known as germline targeting.
Germline-Targeting HIV Vaccine Candidate Prepares Phase 1 Study
ASCO: Increase in Cancer-Related Death Seen During Pandemic
Cancer-related monthly mortality rate higher in April 2020 when health care capacity was most challenged